Q1 Results Round-Up: J&J, Nestlé and P&G

J&J sales rose by 5.0% on a reported basis in Q1 2022 to US$23.4bn, with operational growth of 7.7%. Consumer Health sales fell by 1.5%, but grew 0.8% operationally. Excluding the net impact of acquisitions, divestitures and translational currency, adjusted CH operational sales increased by 1.6%. This was primarily driven by OTC products, with Tylenol and Motrin, upper respiratory products and Imodium major contributors. 

P&G net sales rose by 7% in Q3 fiscal 2022 (Jan-Mar 2022) to US$19.4bn. Excluding the impact of foreign exchange, acquisitions and divestitures, organic sales grew by 10%, driven by a 3% rise in shipment volumes, 5% from increased pricing, and a 2% increase from positive geographic and product mix, with each category growing. Health Care – US$2.7bn, +13% – was once again P&G’s strongest division. Personal Health Care organic sales were up more than 30%, owing to a stronger cough / cold & flu season vs the prior year, as well as innovation in sleep and digestive wellness.

Nestlé sales rose by 5.4% in Q1 2022 to CHF22.2bn (US$23.4bn). Growth was broadly based across most geographies and categories. E-Commerce sales grew by 5.0%, building on 39.6% growth in Q1 2021. Nestlé Health Science, which earlier this month completed the acquisition of a majority stake in Orgain, a leader in plant-based nutrition, advanced by 55.8% to CHF1.4bn (US$1.5bn). Organic growth was 5.6%, building on two consecutive years of double-digit growth, with real internal growth of 4.3% and pricing +1.3%. 

Source: J&J

Nicholas Hall’s Touchpoints: Here at NHC we are in the final countdown for the Athens Conference, already postponed three times because of Covid. I’m looking forward so much to meeting delegates in the old-fashioned way, even if we are still required to wear masks and preserve some form of social distancing.

And we will have a lot to celebrate at the conference. Even though society is not quite ready for the New Normal – the pandemic is not yet over and almost certainly we will face a global recession in the months ahead – I sense a new optimism in the CHC industry. Some of our players are reporting positive and even spectacular results and the pulse of Licensing & Acquisition never slackens.

With less than two weeks to go until our 32nd European CHC Conference & CHC Training Academy Workshop, why not reserve your place now! Taking place in Athens on 4-6 May 2022, industry experts including speakers from Bayer, J&J, Menarini and Teva will explore how as an industry we can move forward with CHC Innovation. Contact elizabeth.bernos@NicholasHall.com to book your seat.

Jeffries London Healthcare Conference

Nicholas Hall’s Touchpoints: On 19th November, it was my great pleasure to moderate the CHC panel at the Jefferies conference. My distinguished panellists were two experienced CHC war horses: Roger Scarlett-Smith, Executive VP UK & USA, Stada, and President UK at Thornton & Ross, part of the Stada group, and formerly a very senior manager at GSK; and Pat Smallcombe, Chairman of Karo Consumer Healthcare and a former Pfizer and J&J top executive. Here follows a summary: 

  • Separation of J&J’s Consumer Health business presents a great opportunity for a company of that size. The CH unit has focused on increasing profitability & market attractiveness and has gone from underperforming from a P&L perspective to growing sales and shares. The agility, cadence & skill sets required for CH, which needs to act more locally, are different to more global, science-led Pharmaceutical and Medical Devices units. The question is if the separation, which will take several years, will detract from the focus on the market 
  • Ongoing impact of Covid varies by category, but the industry is at a crossroads. The huge increase in sales of vitamin D3 & immunity boosters is holding. Half-year data show treatment products are growing very strongly for the first time in many years, particularly in N America, although it is too early to say if this is the beginning of a longer-term trend. Meanwhile, Covid has accelerated trends that were already happening such as sustainability and a preference for trusted brands; the influence of HCPs has increased relative to influencers. In Health & Beauty, the fastest growing sub-category as an idea is vegan endorsement
  • Disproportionate surge in e-Commerce has been driven by the pandemic and is now running at around 12% of the CHC market; DB6 estimates this will double in the next 10 years. Any company that does not have an e-Commerce position will be in trouble in the long-term. Amazon is particularly popular in Germany, UK & USA, although several companies are aiming for a brand.com approach. However, increasing traffic to those sites and setting up an operation like Amazon is extremely expensive. It remains to be seen though if consumers return to physical stores if they do not have to shop online. In a related issue, there has been little evidence of price comparisons in different markets; this is probably more of a trade issue
  • Personalised healthcare has big opportunities, but we are still at the front end. Consumers are sceptical about who owns the healthcare data; they are more trustful of HCPs than tech or pharma companies. At this stage, it is hard to see the return on investments and there are plenty of other areas for growth 
  • M&A moving forwards is an area of interest as recent deals have been positive, with encouraging multiples and stable businesses. The healthcare technology area is also interesting. There is a rich appetite around consolidation. There will be more spin offs, with MNCs offering underutilised assets, such as Nizoral & Compeed, which, with increased A+P, have huge salient equity with consumers. Whether M&A is replacing R&D and NPD is a good question; there must be the right combination of internally-generated innovation vs externally-generated innovation
  • Biggest white space in the CHC market may be a cultural white space where you can execute with reliability, high quality and good customer service, while retaining an entrepreneurial localisation spirit. Getting closer to the consumer and being more relevant using digitalisation is also key, as is being more focused at the right time, with the right product, in the right way

This summary doesn’t do full justice to the wisdom and erudition of the panellists, with a small amount of support by myself. If you would like to hear the whole 45-minute session, please click on the link here.

Q1 2021 Results: CCA Round-up

Five of the Top 6 global CHC marketers have now reported their Q1 2021 results, and the clear common theme is a difficult start to the year as a result of the downturn in cough, cold & allergy sales. Global No.1 GSK reported that Consumer Healthcare sales were down 9% as a direct result of the year-on-year “pantry-loading” comparison, including accelerated purchases across all categories driven by the pandemic, combined with a historically weak cold & flu season. GSK’s Respiratory Health portfolio was down 42% in Q1, with Theraflu and Robitussin declining in double-digits, and Contac hit by a high single-digit fall, all adversely impacted by a lower cold & flu season.

Global No.2 J&J reported that Consumer Health worldwide operational sales were down 2.9%, primarily driven by negative prior-year comparisons related to Covid pantry loading in Q1 2020, mainly in OTC products, which declined by 14.8% in Q1 2021 as a result of lower cough, cold & flu incidences. This was partially offset by growth in Listerine mouthwash, Johnson’s baby care products, international skin health / beauty products and Nicorette sales outside the USA.

Sanofi’s Consumer Healthcare sales decreased by 7.3% in Q1 2021, primarily reflecting the weak cough / cold season, as well as a high base for comparison in Q1 2020 and divestments of non-core products. Allergy fell by 6.2%, while Cough & Cold sales were down 59.4% in Q1 2021. This heavy decline was offset by gains for Digestive Wellness (+14.6%), Physical Wellness and Mental Wellness (+18.8%) products. In USA and Rest of the World, growth of the Digestive and Mental Wellness categories partially offset lower Cough / Cold and Pain sales, but in Europe CHC sales fell by 19.3% in Q1.

Reckitt Q1 2021 net revenue was up 4.1% (like-for-like), and e-Commerce was +24%, accounting for 13% of total net revenue, driven by increased investment. Health fell 13.0%, reflecting a volume decline of 14.2% and price / mix improvements of 1.2%, as overall price growth was offset by relatively higher trade investment in North America. The OTC portfolio fell by just under 40%; in addition to challenging comparatives owing to significant pantry-loading in March 2020, this reflects an exceptionally weak cough, cold & flu season – estimated to be around 90% lower than the prior year – resulting in declines for Strepsils, Nurofen and Mucinex.

P&G’s Health Care organic sales were up 3% in Q1 2021, while Personal Health Care organic sales fell by mid-single digits, primarily owing to pandemic-related increases in consumer and retailer inventories in the base period and a weaker than average cough, cold & flu season. Representing 14% of global sales, e-Commerce sales increased by around 50% fiscal year-to-date, with no noticeable change in shopping trends in the quarter. CFO Andre Schulten said in an earnings call that a portion of the impact of commodity cost challenges in the next fiscal year would be offset with price increases in the baby care, feminine care and adult incontinence businesses, which will go into effect in mid-September 2021.

Celine Waller VP, DB6 comments: The poor CHC results reported were set against a robust performance in Q1 2020 when consumers were stockpiling ahead of lockdown restrictions (J&J’s OTC business increased operationally by 25.8% in Q1 2020!) and we expect that they will improve as the year goes on. However, 2021 is expected to be affected by a very weak cough / cold season as lockdowns (still in effect in many markets), social distancing, hygiene measures and mask-wearing continue to suppress incidence of respiratory illnesses, while there are some doubts about whether the high consumption levels of disinfectants and immune-boosting supplements can be sustained. As such, we have lowered our expectations of CHC growth in 2021 to 2.3% in the retail market. However, as highlighted in the P&G results, the 2020 boom in e-Commerce sales is continuing into the current year and we forecast that combined CHC sales in all channels will come out at a respectable 4.0% in 2021.

We are pleased to announce that our annual bestselling report, Nicholas Hall’s CHC Yearbook 2021, is now published digitally! You can analyse key players’ performance, hot topics, global retailing, the Top 15 markets and much more! Print copies will follow soon. For more information, or to order your copy, please contact melissa.lee@NicholasHall.com.

Ad Watch: 2020 A+P Trends

Two advertising stories caught our attention this week. First was the news that P&G is no longer the world’s No.1 advertiser, with Amazon taking the top spot, according to Ad Age, which publishes an annual list of the largest marketing spenders. The online retail giant spent US$11bn on A+P in 2019, 34% ahead of 2018, when it ranked fifth. P&G was placed second, with US$10.7bn in ad spending in its fiscal year ending in June 2020, while L’Oréal came in at No.3, spending US$10.3bn in 2019. Ad Age notes: “2020 ad spending figures for top marketers are going to be depressed – with exceptions for some advertisers that increased spending to take advantage of market opportunities amid the coronavirus pandemic.”

Secondly, Contagious published its review of the biggest trends in advertising and the best campaigns of 2020. Among the Top 25 campaigns of the year, there were several healthcare & beauty brands listed, including RB’s Dettol, backed by a huge social media initiative on TikTok (#HandWashChallenge) in India. According to Contagious, the campaign involved some of India’s biggest influencers and generated over 125bn views on Dettol’s TikTok page.

Another campaign highlighted was Bayer’s support of Berocca in Vietnam, an A+P initiative that we also profiled earlier this year. Working with digital agency Carnival, Bayer devised the Get Supercharged at 2pm campaign, creating a TikTok music video and encouraging people to post videos of themselves copying its dance moves by offering prizes for the most views. This led to 70,000 videos being created by people participating in the #BeroccaMango2PM hashtag challenge. The campaign directed users to e-Commerce platform Shopee, where they could purchase Berocca bundles and combos. Online sales rose 223% compared with the same period the year before, according to Bayer, while offline sales also increased 32%.

Various beauty brands also featured in the Contagious roundup of the Top 25 campaigns of 2020, most notably P&G’s Dove, which was backed by a Courage Is Beautiful campaign at the height of the pandemic, highlighting the strength and resilience of frontline healthcare workers. The Contagious report also cited recent YouGov research that places both Dettol and J&J’s Tylenol among the Top 25 Best Global Brands 2020 in terms of consumer awareness.

You can review innovation by region and country, including a review of the most active marketers globally in terms of NPD, in our recent report from CHC New Products Tracker, Innovation in CHC. This report also highlights ingredient and delivery format trends, showcases 100 innovative products in 2019, plus much more. For further details, or to order your copy, currently available with a 30% discount until 31 December, please contact melissa.lee@NicholasHall.com without delay. 

Market Movers Q1: CCA, VMS brands among fastest movers

CHCINACTION

In this week’s blog, we take a closer look at our newly published Market Movers data for MAT Q1 2020, which highlights the brands that performed best and worst in terms of value sales growth or decline in that period. Certain marketers like RB, which last week reported a 12% rise in its OTC portfolio in Q2 2020, have found success from having a well-positioned portfolio of power brands in fast-growing, Covid-driven CHC categories, such as cough & cold remedies (Mucinex), immunity supplements (Airborne) and antiseptics & disinfectants (Dettol).

P&G also reported double-digit organic growth of its Personal Health Care portfolio in Q2 (fiscal Q4), powered by Vicks, which continues to gain share. Vicks NyQuil / DayQuil combo packs were among the six fastest-growing brands in MAT Q1 2020, along with one of China’s leading systemic cold & flu remedies, 999 Gan Mao Ling. VMS products also featured strongly among the Top 6 fastest-growing brands, with Olly and Emergen-C performing well in the US market thanks to their stress / immunity positioning, and Double Whale Vitamin D Drops achieving high growth in China. J&J’s Tylenol, the No.1 analgesic brand globally, also continues to produce dynamic Covid-driven growth.

Screen Shot 2020-08-03 at 12.22.04.png

Asia-Pacific was the region that underperformed most in MAT Q1 2020 – achieving just 3.4% growth vs 6.3% for North America and Europe – so it is no surprise that five of the Top 6 worst-performing brands are from China or Japan. Tonics & cure alls was the subcategory most responsible for Asia-Pacific’s relatively low growth, with category sales down 25% in China, owing to issues with donkey breeding that have resulted in rising raw material costs and subsequent price rises, affecting two brands in particular – Dong-e E-jiao and Fu Fang E Jiao Jiang – while Hong Mao Medicated Wine was affected by negative claims.

OTC tonic drinks is another VMS subcategory hit by declining sales, with a continued downturn in Japan where the old, male consumer base is retiring and brands face competition from energy drinks. Takeda’s Alinamin EX was among the brands that declined fastest in MAT Q1 2020. Another CHC subcategory affected by weaker sales in Q1 was antacids, as a result of the withdrawal of ranitidine-based antacids from the market owing to concerns around NDMA in the formulation. Sanofi’s Zantac was among the key brands impacted, with Zantac 150 in sharp decline in the US market.

Today is the last chance to pre-order our upcoming Analgesics 2020: Assessing the Current & Future Self-Care Market for Pain Relief at the discounted rate and save up to GB£1,800! Contact melissa.lee@NicholasHall.com to order or find out about special discounts available on purchases of more than one report title!

Top 2 brands powering global CHC growth

CHCINACTION

Our blog this week looks at the performance of the Top 10 global consumer healthcare brands, in the context of the 5.6% upturn for the global CHC market in the year to end-March 2020. Inevitably, analgesics and cough, cold & allergy brands have enjoyed the highest rates of growth thanks to Covid-driven demand, with the Top 2 global brands, Vicks (+15.4%) and Tylenol (+18.3%), performing particularly well.

P&G’s CCA range Vicks now generates global sales of nearly US$1.5bn, and its double-digit growth in the MAT Q1 2020 period was powered by dynamic performances in Latin America and North America. In fact, high growth in the US market was behind the double-digit global upturns for both Vicks and J&J’s Tylenol, the latter generating sales of close to US$1bn in its home market.

Top 10 brands Q1 2020.jpg

GSK markets four of the other Top 10 brands, including its powerful triumvirate of painkillers – Advil, Voltaren and Panadol. Growth for Advil and Panadol improved markedly in Q1, thanks to accelerated purchases as a result of Covid-19, while Voltaren experienced flat sales in the quarter. That said, the recent US Rx-to-OTC switch of Voltaren Arthritis Pain is expected to provide a significant boost to brand sales in Q2.

Halls also saw growth accelerate in Q1, although not to the same extent as other CCA brands like Mucinex, which rediscovered growth during the first quarter of 2020 to leap ahead of J&J’s Nicorette to reclaim the global No.9 spot. VMS brands Centrum and Nature Made missed out on the overall surge in demand for CHC products in Q1 – in general, growth in the VMS market has been focused primarily on immune supplements and vitamin C products.

Pre-order our upcoming Analgesics 2020: Assessing the Current & Future Self-Care Market for Pain Relief report before 31 July to save up to GB£1,800! Please contact melissa.lee@NicholasHall.com to order or to find out about special discounts available on purchases of more than one report title!

Covid-19: France advises against ibuprofen to treat symptoms

CHCINACTION

France’s Health Minister Olivier Véran delivered a message via his Twitter account over the weekend, advising against taking anti-inflammatory medicines (ibuprofen, cortisone, etc) to treat Covid-19 symptoms, as they could be an aggravating factor for the infection. His advice for those with a fever was to take paracetamol instead. Patients already on anti-inflammatory drugs for other illnesses, or anyone with any questions, are advised to seek advice from their doctor.

Public health interventions like this, with directives specifically citing which OTC medicines to take or not take, are rare and so the story was picked up by major news outlets in the UK (Guardian), USA (New York Times) and elsewhere. According to a report in The Local, Véran’s tweet prompted several members of the public to ask for the source of his reasoning on not taking ibuprofen to treat Covid-19 symptoms. The main concern appears to be that anti-inflammatories have an “immunosuppressive effect“, plus the background in France is that medicines agency ANSM has already removed medicines containing paracetamol, ibuprofen and / or aspirin from the self-selection list in January 2020 to reinforce the advisory role of the pharmacist and guarantee safe use.

81eQ4AfKNML._AC_SL1500_.jpg

Meanwhile, the effect of the Covid-19 pandemic on sales and availability of painkillers in other markets is already becoming evident, with UK retailer Boots imposing a limit of two items per customer on cough & cold and pain medicines and US marketer J&J reporting a spike in demand for its Tylenol range and other self-care products. In the wake of the Covid-19 outbreak, and India’s decision last week to restrict the export of some ingredients (including paracetamol), there have been fears of shortages and disruptions to supply chains, but J&J said it did not anticipate a shortage of Tylenol and that it was taking all possible measures to maximise availability of its consumer healthcare range.

The good news is that we have extended the campaign entry criteria and deadline for our 2020 Marketing Awards! Coinciding with the new event dates, the Awards will now be presented on 30 September during our 31st European Conference in Athens on 29 September–1 October 2020. If you’re proud of your latest campaign or brand, ensure that you enter before the new deadline of 14 August! For more information on entry criteria, contact jennifer.odonnell@NicholasHall.com without delay.

CHC Adjacencies Fuelling Digital Marketing Innovation

otcinaction

A new report from Nicholas Hall examines effective digital marketing strategies for consumer health players and the fast-growing online channel for OTCs. In this week’s blog, we examine which consumer healthcare categories, brands and companies most fully embraced social media marketing in 2019, and summarise the report’s findings.

Given the tight regulations surrounding the promotion of registered OTC medicines on social media, it’s no surprise that the subcategories where we’ve recorded the most digital marketing activity in 2019 – using our OTC New Products Tracker tool – were adjacent categories in Lifestyle OTCs, VMS and dermatologicals. Cannabis / CBD recorded the highest number of innovations backed by social media promotion in 2019, followed by lip care and probiotics.

Of the Top 20 brands that recorded the highest number of innovations in 2019 backed by social media promotion, lip care products Eos (Eos) and ChapStick (formerly Pfizer, now GSK) were at the top of the tree. For example, Eos Vampire Kiss was supported by an Instagram campaign in the run-up to Halloween. CBD companies such as Hilo, CBDfx and Ignite – the latter backed by professional poker player and social media celebrity Dan Bilzerian – have also used digital marketing in 2019 to support their new products. Among VMS brands, Irwin Naturals, Zarbee’s Naturals (J&J) and Olly (Unilever) were all well-supported on social media, especially Facebook.

Top 20 brands.jpeg

Below are some of the findings from the new Nicholas Hall report:

  • It is vital that approaches to digital marketing are differentiated across digital and social media channels
  • Most consumers trust social media for healthcare advice, making an engaging social media strategy critical
  • Rapid adoption of digital technologies and evolving shopping behaviours are transforming e-Commerce into a key channel in consumer healthcare
  • Consumers will generally shop where it is most convenient, so understanding where they are shopping online is vital
  • Mobile is consumers’ constant companion so all content should be accessible on mobile devices
  • Since the virtual shelf is infinite, standing out from competitors online requires orchestrated brand communication

Comment from Ian Crook, Managing Editor, Nicholas Hall’s Reports: When considering how to target consumers via digital channels, marketers must note that different demographic groups use different social media platforms, and in diverse ways. Content consumption is diversifying just as audiences are broadening; the modern consumer leads a very busy life and can be easily distracted, posing challenges to effective engagement. Fostering consumer connections is vital, and whichever means of communication is used – live streaming, chatbots, social media messaging, etc – interacting with consumers is essential. Marketers cannot win everywhere or invest in all platforms, so choosing the appropriate medium is an important step in planning an effective digital campaign.

The new report features many more findings, backed by relevant case studies, including a look at consumer influencers, the benefits of a direct-to-consumer strategy, the digital strategies of the OTC Top 10, as well as the differing regulatory situation for online sale of medicines across markets, plus much more. To purchase your copy of Digital Marketing & e-Commerce, or for more details, please contact melissa.lee@NicholasHall.com.

Natural & Organic a focus for M&A and innovation

otcinaction

Continuing our series of blogs on the 10 Infinity Zones for future CHC growth recently outlined by Nicholas Hall, in this edition we take a closer look at natural & organic products. This is by no means a new trend, but it’s certainly one increasingly on the radar of multinationals, as exemplified by J&J’s recent purchase of Zarbee’s Naturals.

Among herbal & natural cough remedies, Zarbee’s has been gaining share on rivals such as Little Remedies, Hyland’s and Chestal, while also growing faster than most medicated OTC cough remedies. Another growth driver in the US market is Maty’s all-natural and organic range, including honey-based cough remedies, while Unilever recently bought Olly Nutrition, another range of VMS products with a strong emphasis on natural ingredients, such as the 10 phytonutrients in its Super Foods Multi line.

olly-kids-superfoods-front_1700x

A+P for most herbal & natural products often emphasises the importance of quality standards and – increasingly – organic and responsibly-­sourced ingredients. In China, the No.1 probiotic brand Biostime (Health & Happiness for Institut Rosell) is promoted on the basis of the organic sourcing of its ingredients, while marketing involving brand ambassador Juliette Binoche also emphasises the natural heritage of the brand.

According to OTC New Products Tracker, the number of launches that include the word “organic” either in their branding or list of ingredients is growing fast, with 246 innovations in 2018 vs 168 in 2017 and just 81 in 2016. Over half of these products are unsurprisingly classified as vitamins, minerals & supplements, however there is also a growing number of “organic” Lifestyle OTCs, especially among medical cannabis products, sedatives & sleep aids and stimulants.

Last chance to pre-order Nicholas Hall’s New Paradigms for CHC 2019: Over the Horizon, written by Nicholas himself! Examine each aspect of the CHC industry in 20 chapters, with a focus on major issues including Regulation, Pharmacy Point-of-Care, M&A, Switch and much more. Nicholas will also unveil the “infinity zones” he has identified as being crucial to the future growth of the industry. In addition to this, you can upgrade your purchase to include a customised in-house presentation or webinar with Nicholas for an additional GB£10,000. To find out more or to place your order, please contact melissa.lee@NicholasHall.com.

CHPA Report & Conference

otcinaction

Last week, to tie in with its Annual Executive Conference (AEC), the Consumer Healthcare Products Association released a white paper that found, on average, every dollar spent on OTC medicines saves the US healthcare system around US$7.20, resulting in nearly US$146bn in savings annually. CHPA President & CEO Scott Melville commented that the “healthcare system undervalues the contribution of our industry’s products”, and explained that the research will support legislative initiatives promoting financial incentives for consumers to buy OTCs using health insurance flexible spending plans.

OTCD_Infographics_data_5

Done in partnership with IRI, the study was conducted in part to raise the profile of OTC products in USA. It found that around 90% of people who buy an OTC product for a condition would seek medical care if the OTC product had not been available. The study analysed nine OTC categories to identify the primary contributors of cost savings to the healthcare system. The categories include allergy, analgesics, antifungals, cough / cold / flu, lower GI, medicated skin, upper GI, sleep and smoking control. The research showed that OTC medicines provide additional value through expanded access to more than 27mn consumers who would otherwise forgo treatment – more than 13mn Americans for allergies alone.

OTCD_Infographics_data_3

Writing from Florida, Nicholas Hall said: “Trust was a major theme of CHPA’s Annual Executive Conference … Edelman presented data showing that consumer trust of healthcare is improving after plummeting last year. Speakers agreed that trust goes beyond building brands. In a session I moderated on Tuesday, Bayer CH President Heiko Schipper said that our industry needs to, “articulate better what we do. We are doing a lot of good things like being responsible for the environment and employee diversity”.

Taisho Executive VP Ken Uehara agreed: “Trust can’t be built instantly, certainly for our company, it’s our most important asset.” Alan Main, Executive VP, Sanofi, commented that in the past it was about building the brand: “I still think the brand comes first in people’s minds, but we have to look after the brands, not just for five years but for 30-40 years.” Katie Devine, who is moving into a new leadership role at J&J, said companies can choose not to reply to every tweet, but should maintain a fact-based conversation about being responsible in the treatment of employees, the population and planet.

Other questions I addressed to the Leadership Panel concerned the lack of Rx-to-OTC switch (Alan Main said switch has an important role to play in the future of self-care); CBD (all panellists believe it will develop well beyond the current US$500mn quoted by IRI, although Katie’s point, “I know how to switch from Rx to OTC, but not from illegal to legal”, was well taken); and the number one item on their wish list — speed to market and improved innovation were favourites … I liked the concentrated format of this year’s AEC, with two half-day sessions, which allowed time for networking, and was proud to have been one of three Preferred Sponsors of the meeting, in the good company of Google and the Emerson Group.”

Nicholas Hall will discuss the latest Market Trends and Innovation impacting the CHC market at our annual North American CHC Conference (26-27 June) in collaboration with our partners EverythingHealth. As well as the chance to network with other industry players, you can hear from Google, Jefferson Health, Persuadable Research and other industry experts. Don’t hesitate — book before 31 March to save with our generous early-bird booking discount! To find out more about this event, please contact elizabeth.bernos@NicholasHall.com.